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Abstract
Background: DNA-damage-inducible transcript 3 (DDIT3), a candidate tumor suppressor gene (TSG), has been found 
involved in the regulation of cellular growth and differentiation. The epigenetic changes of TSGs are recently 
recognized as an abnormal mechanism contributing to the development of chronic myeloid leukemia (CML). The aim 
of this study was to investigate the methylation status of DDIT3 gene in CML patients.
Methods: The methylation status of DDIT3 promoter was detected in the bone marrow mononuclear cells from 53 
patients with CML using methylation-specific PCR (MSP). The expression levels of DDIT3 and bcr/abl transcript were 
determined by real-time quantitative PCR (RQ-PCR). Clinical data of these patients were collected and analyzed.
Results: The aberrant methylation of DDIT3 gene promoter was found in 35 of 53 (66%) CML cases. Correlation was not 
found between DDIT3 promoter hypermethylation and the age, sex, hemoglobin concentration, platelet counts, 
chromosomal abnormalities, bcr/abl transcript, and staging of CML patients (P > 0.05), but found between DDIT3 
promoter hypermethylation and WBC counts of CML cases (R = 0.781, P < 0.001). The level of DDIT3 transcript in CML 
patients was significantly lower than that in controls (median 3.28 vs 19.69, P < 0.001), however, there was no difference 
in the level of DDIT3 transcript between methylation-positive CML cases (0.05-65.32, median 2.13) and methylation- 
negative CML cases (0.12-126.04, median 3.92) (P > 0.05).
Conclusion: Our results demonstrate that aberrant methylation of DDIT3 occurs in CML frequently.
Background
Chronic myeloid leukemia (CML) is a stem cell disease
characterized by excessive accumulation of clonal myel-
oid cells in hematopoietic tissues. Almost all patients
with CML present the common cytogenetic abnormality
of the t(9;22) and the bcr/abl fusion gene which is gener-
ated by the translocation. Clinically CML can be divided
into three phases: the chronic phase (CP), the accelerated
phase (AP), the blast crisis (BC) [1,2]. BC is the last stage
of CML disease progress, in which hematopoietic differ-
entiation become arrested and immature blasts accumu-
late in the bone marrow and spill into the circulation. The
mechanisms responsible for transition of CP into BC
remain poorly understood [3].
In the pathogenesis of leukemias and other cancers,
gene silencing by aberrant DNA methylation is a frequent
event [4,5]. The methylation of several tumor suppressor
genes (TSGs) including E-cadherin, death-associated
protein kinase (DAPK), estrogen receptor (ER), and the
cell cycle regulating genes (P15INK4B and P16INK4A), has
been confirmed associated with the development and
progression of CML [6-9].
DNA-damage-inducible transcript 3 (DDIT3), also
named CCAAT/enhancer binding protein zeta (C/EBPζ),
is expressed ubiquitously and can be induced by a wide
variety of treatments such as DNA lesion, hypoglycaemia,
radiation and cellular stress. Several studies have con-
firmed the role of DDIT3  in the regulation of cellular
growth and differentiation [10-13]. The overexpression of
DDIT3  transcript has been found to induce increased
apoptosis of myeloid cells and block cells in the progres-
sion from G1 to S phase [14,15]. The level of DDIT3 tran-
s c r i p t  h a s  b e e n  r e v e a l e d  d o w n - r e g u l a t e d  i n  m y e l o i d
malignancies in our previous study [16]. The other five
members of C/EBP proteins also play important roles in
cellular proliferation and terminal differentiation of
hematopoietic cells. Recently, two members of C/EBP
family,  C/EBPα  and  C/EBPδ, have been found to be
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silenced by aberrant methylation in acute myeloid leuke-
mia (AML) [17-19]. However, the methylation status of
DDIT3 promoter has not yet been studied in leukemia.
The primary aim of this study is to investigate the methy-
lation status of DDIT3 promoter in CML patients and
determine the association of DDIT3 methylation with the
patients' clinical features.
Materials and methods
Patients and samples
Fifty-three cases of CML seen at the Affiliated People's
Hospital of Jiangsu University were selected for this study
based on the availability of stored leukemic cells. Thirty-
five patients were in CP , three in AP , and fifteen in BC.
The diagnosis of CP, AP and BC was established accord-
ing to conventional criteria. Briefly, CP was defined as
having within the peripheral blood and bone marrow less
than 10% blasts, less than 20% basophils, and less than
30% blasts plus promyelocytes, with t(9:22) translocation
or bcr/abl transcript. AP was defined as having blasts ≥
10%, blasts and promyelocytes ≥ 30%, basophils ≥ 20%,
platelets ≤100 × 109/L unrelated to therapy, or cytoge-
netic clonal evolution. BC was defined as the presence of
≥ 20% peripheral or bone marrow (BM) blasts, or
extramedullary blastic disease. The BM samples from all
patients were harvested at the time of diagnosis and BM
mononuclear cells (BMNCs) were isolated using Ficoll
solution and washed twice in PBS and then frozen in -
80°C. BM samples collected from thirteen donors of BM
transplantation were used as controls. Placenta tissue of
one healthy pregnant woman was used as the sample to
prepare positive controls of methylated and unmethy-
lated DNA. Informed consents were provided according
to the Declaration of Helsinki.
RNA isolation and Real-time quantitative PCR (RQ-PCR)
Total RNA was extracted from the BMNCs of CML
patients by the guanidinium thiocyanate/acid phenol
method using Trizol reagent (Invitrogen Life Technolo-
gies, USA) in accordance with the manufacturer's stan-
dard method. 2 μg of total RNA was reverse transcribed
into cDNA by using random primers, 200 U of MMLV
reverse transcriptase (InVitrogen), 0.5 mM dNTPs, 10
mM dithiothreitol, and 25 U of RNase inhibitor (InVitro-
gen). 40-μL RT reaction was performed at 37°C for 60
min, then at 95°C for 5 min. cDNA was stored in -20°C
until assayed. DDIT3 and bcr/abl transcripts were quanti-
fied using RQ-PCR established previously [7,16].
DNA isolation and bisulfite modification
DNA was isolated from BMNCs using Genomic DNA
Purification Kit (Gentra, Minneapolis, MN, USA). 1 μg of
genomic DNA was modified as described in manufac-
ture's instruction using the CpGenome™ DNA Modifica-
tion Kit (Chemicon, Ternecula, Canda). Modified DNA
was resuspended in water and used immediately or
stored at -80°C until used.
Methylation-specific polymerase chain reaction (MSP)
DNA methylation status in the CpG island of DDIT3 pro-
moter was determined by the MSP procedure described
previously [20]. Primer sequences for the methylated (M)
MSP reaction were 5'-GGTTCGATATTACGTC-
GATTTTTTAGC-3' (forward) and 5'-GCCGACATT
AACCCCG-3' (reverse), and primer sequences for the
unmethylated (U) MSP reaction were 5'-ATTTTTG-
GGTTTGATATTATGTTGATTTTTTAGTG-3' (for-
ward) and 5'-CAAAAAA TAACACACCAACATTA
ACCCCA-3' (reverse). 25 μl of reaction mixture con-
tained 1 × PCR buffer (containing 15 mmol/L MgCl2), 2.5
mmol/L dNTPs, 0.4 pmol/L primers, 1 U Hot start DNA
polymerase (Takara, Tokyo, Japan), and 2 μl of modified
DNA. PCR conditions were 95°C for 5 min, 35 cycles for
30 s at 94°C, 30 s at 63.1°C (M) or 62°C (U), 30 s at 72°C
followed by a final 7 min extension step at 72°C. Amplifi-
cation was carried out in a 9600 Perkin-Elmer Thermal
Cycler (PerkinElmer Inc., Ramsey, MN, USA). Placenta
DNA treated in vitro with SssI methyltransferase (New
England Biolabs, Beverly, MA, USA) and untreated were
used as positive controls for methylated and unmethy-
lated templates, respectively. Negative control samples
without DNA were included for each set of PCR. PCR
products were analyzed on 3% agarose gels and visualized
under UV illumination. To verify successful bisulfite
modification of the DNA, a sequence containing cyto-
sines would not be amplified after bisulfite modification
by using primers that would only give an amplified prod-
uct if the cytosines in the template sequence were not
converted to uracils. For this purpose, a region of the β-
actin promoter was amplified with every modified DNA
sample. Samples that did not give a band were considered
completely modified and further used for MSP analysis.
Those cases were defined as methylation positive if their
sample showed a visual band amplified with methylated-
specific primers, even if the band was faint. All positive
results were confirmed in at least two MSP analyses.
Using 80 ng totally methylated placenta DNA serially
diluted by totally unmethylated DNA, we determined
that the sensitivity for a clear detection of a methylated
allele was 2%. Positive products of M and U reaction from
one patient in CP were cloned and sequenced (Shanghai
GeneCore BioTechnologies Co., Ltd., Shanghai, China).
Conventional cytogenetic analysis
Conventional cytogenetic investigation was carried out
for these patients. Chromosomes were prepared rou-
tinely by the direct method or short-term culture of BM
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phases. Chromosomal abnormalities were described
according to the International System for Human Cytoge-
netic Nomenclature. CML patients were classified as
three subgroups according to the types of cytogenetic
abnormalities: t(9;22), variant t(9;22), and t(9;22) with
additional alteration.
Statistical analysis
Statistical analysis was performed using the SPSS 13.0
software package (SPSS, Chicago, IL, USA). Chi-square
analysis and Fisher exact test were carried out to compare
the difference of frequencies between groups of patients.
Mann-Whitney's U-test was carried out to the difference
of age, level of DDIT3 and bcr/abl transcript between the
methylated and the unmethylated groups. The correla-
tion between the frequency of DDIT3 promoter methyla-
tion and the clinical and hematologic parameters was
analyzed with Spearman's rank correlation. For all analy-
ses, the P-values were two-tailed, and a P-value of < 0.05
was considered statistically significant.
Results and discussion
Thirty-five patients (66%) showed DDIT3 hypermethyla-
tion that was not found in all controls (P < 0.001). The
representative results of MSP were shown in Fig 1. The
sequencing of PCR products from one CML patient con-
firmed the MSP results, shown in Fig 2. There were no
significant correlations between the methylation status of
DDIT3 promoter and the clinical features, such as age,
sex, initial hemoglobin level, platelet counts, chromo-
Figure 1 MSP results of DDIT3 gene in CML. U and M represent PCR 
results by using primer sets for methylated and unmethylated DDIT3 
gene, respectively. 1: positive control (positive controls of methylation 
and unmethylation are genomic DNA of placenta which is modified 
with or without M.SssI); 2: sample of one BM donor; 3,4: samples of two 
cases at CP; 5: sample of one case at AP; 6: sample of one case at BC; 7: 
ddH2O; Mark: Gene Ruler™ 100 bp DNA Ladder.
Figure 2 The sequencing results of MSP products in one patient with CML. I: The sequencing result of methylated product, CG was not changed 
after bisulfite treatment; II: The sequencing result of unmethylated product, T was replaced by C after bisulfite treatment.Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:54
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somal abnormalities, and bcr/abl transcript (P  > 0.05).
The level of DDIT3 transcripts in CML patients (0.05-
126.04, median 3.28) was significantly lower than that in
controls (6.19-82.16, median 22.37) (P < 0.001). Although
methylation-positive CML cases had lower DDIT3 tran-
script level than those methylation-negative cases, how-
ever, the difference was not significant (Table 1). This
result may be associated with the low number of patients
studied. Other mechanisms besides DNA methylation
might be also involved in the regulation of DDIT3 expres-
sion. More cases should be further studied to determine
the impact of DDIT3 methylation on the regulation of
transcription.
The correlation was found between DDIT3 promoter
hypermethylation and white blood cells (WBC) (R = -
0.781,  P  < 0.001). Using partial correlation analysis to
exclude the effect of staging, DDIT3 promoter hyperm-
ethylation was also correlated with WBC (R = -0.474, P =
0.001). WBC of patients with methylation was signifi-
cantly lower than that of patients without methylation
(Table 1). We postulate that the down-regulation of
DDIT3 transcripts caused by promoter methylation fails
to induce mitotic cessation of injured cells, which eventu-
ally results in the delivery of DNA lesions to offspring
cells and the susceptibility to carcinogenesis. However,
the offspring cells gaining DDIT3 methylation might be
prone to apoptosis or growth inhibition owing to other
mechanisms.
The frequencies of DDIT3 promoter hypermethylation
in CML patients in CP, AP and BC were shown in Table 1.
However, correlation was not found between the fre-
quency of DDIT3 promoter hypermethylation and differ-
ent CML stages (P > 0.05). Our results suggested that the
methylation of DDIT3 promoter might occur in the early
stage of CML development. Further study on a more
number of CML patients is needed to explore the role of
DDIT3 methylation in the progression of CML.
C/EBP genes are believed to be critically involved in
hematopoietic differentiation and leukemogenesis. Espe-
cially, the crucial role of C/EBPα in lineage determination
during normal hematopoiesis is well established. C/EBPα
mutations, contributing as an early event to leukemogen-
esis by inhibiting myeloid differentiation, are found in 10-
15% of AML cases [19]. Recently, hypermethylation of C/
EBPα  promoter has also been identified in 12-51% of
AML cases [18,19]. The systematic analysis has revealed
that C/EBPα mutations or hypermethylation are associ-
ated with favorable karyotype or prognosis [18,19].
Hypermethylation of another C/EBP member, C/EBPδ,
has been revealed in 35% AML patients [17]. These stud-
ies indicate that epigenetic alterations of C/EBP genes are
Table 1: Correlation between methylation of DDIT3 gene and the clinical characteristics of CML patients.
Status of DDIT3 methylation
Patient's parameters Patients with methylated 
DDIT3  (n = 35)
Patients with unmethelated 
DDIT3  (n = 18)
Total 
(n = 53)
P value
Ages (yr) 1 48 (21-73) 40 (17-83) 45 (17-83) 0.225
Sex (male/female) 28/7 10/8 38/15 0.106
WBC (×109/L) 1 38.0 (2.2-178.6) 161.8 (4.1-235.2) 75.6 (2.2-235.2) 0.007
Hemoglobin (g/dL)1 9.9 (4.9-14.8) 9.3 (5.2-14.3) 9.5 (4.9-14.8) 0.963
Plateletcounts (×109/L) 1 264 (20-1494) 263 (24-870) 264 (20-1494) 0.844
Cytogenetics 0.542
t(9;22) 26 (63%) 15 (37%) 41
variant t(9;22) 2 (100%) 0 (0%) 2
t(9;22) with additional 
alteration
7 (70%) 3 (30%) 10
Staging 0.256
CP 24 (68%) 11 (32%) 35
AP 3 (100%) 0 (0%) 3
BC 8 (53%) 7 (47%) 15
bcr/abl transcript 4.82 (0.28-877.94) 3.37 (0.26-221.77) 3.96 (0.26-877.94) 0.583
DDIT3 transcript 2.13 (0.05-65.32) 3.92 (0.12-126.04) 3.28 (0.05-126.04) 0.152
WBC, white blood cells; CP, chronic phase; AP, accelerated phase; BC, blast crisis. 1 Median (range).Wang et al. Journal of Experimental & Clinical Cancer Research 2010, 29:54
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involved in leukemia and can be used for disease stratifi-
cation as well as therapeutic targets.
In conclusion, we demonstrate that aberrant methyla-
tion in the CpG island of the promoter region of DDIT3
gene is a common event in CML. However, further study
will be needed to determine the role of DDIT3 methyla-
tion in the development, progress, and prognosis of
CML.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
QJ and LJY designed the study, analyzed the data and wrote the manuscript;
WY, LJ and YDM performed all experiments; QZ and ZZH gave assistance with
technical performance and contributed to the writing of the manuscript.
Acknowledgements
This study was supported by Jiangsu Province's Key Medical Talent Program 
(RC2007035) and Social Development Foundation of Zhenjiang (SH2006032).
Author Details
1Department of Hematology, Affiliated People's Hospital of Jiangsu University, 
Zhenjiang, Jiangsu, 212002, PR China and 2Department of Hematology, The 
First Hospital of Nanjing Medical University, Jiangsu Provincial People's 
Hospital, Nanjing, Jiangsu, 210029, PR China
References
1. Quintás-Cardama A, Cortes JE: Chronic myeloid leukemia: diagnosis and 
treatment.  Mayo Clin Proc 2006, 81:973-988.
2. Melo JV, Barnes DJ: Chronic myeloid leukaemia as a model of disease 
evolution in human cancer.  Nat Rev Cancer 2007, 7:441-453.
3. Calabretta B, Perrotti D: The biology of CML blast crisis.  Blood 2004, 
103:4010-4022.
4. Baylin SB, Herman JG: DNA hypermethylation in tumorigenesis: 
epigenetics joins genetics.  Trends Genet 2000, 16:168-174.
5. Esteller M: Aberrant DNA methylation as a cancer-inducing 
mechanism.  Annu Rev Pharmacol Toxicol 2005, 45:629-656.
6. Issa JP, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, 
Kaufmann SH, Baylin SB: The estrogen receptor CpG island is 
methylated in most hematopoietic neoplasms.  Cancer Res 1996, 
56:973-977.
7. Qian J, Wang YL, Lin J, Yao DM, Xu WR, Wu CY: Aberrant methylation of 
the death-associated protein kinase 1 (DAPK1) CpG inland in chronic 
myeloid leukemia.  Eur J Haematol 2009, 82:119-123.
8. Melki JR, Vincent PC, Brown RD, Clark SJ: Hypermethyation of E-cadherin 
in leukemia.  Blood 2000, 95:3208-3213.
9. Herman JG, Civin CI, Issa JP, Collector MI, Skarkis SJ, Baylin SB: Distinct 
patterns of inactivation of p15INK4B and p16INK4A characterize the 
major types of hematological malignancies.  Cancer Res 1997, 
57:837-841.
10. Maytin EV, Habener JF: Transcription factors C/EBP alpha, C/EBP beta, 
and CHOP (Gadd153) expressed during the differentiation program of 
keratinocytes in vitro and in vivo.  J Invest Dermatol 1998, 110:238-246.
11. Tang QQ, Lane MD: Role of C/EBP homologous protein (CHOP-10) in the 
programmed activation of CCAAT/enhancer-binding protein-beta 
during adipogenesis.  Proc Natl Acad Sci USA 2000, 97:12446-12450.
12. Pereira RC, Delany AM, Canalis E: CCAAT/enhancer binding protein 
homologous protein (DDIT3) induces osteoblastic cell differentiation.  
Endocrinology 2004, 145:1952-1960.
13. Coutts M, Cui K, Davis KL, Keutzer JC, Sytkowski AJ: Regulated expression 
and functional role of the transcription factor CHOP (GADD153) in 
erythroid growth and differentiation.  Blood 1999, 93:3369-3378.
14. Friedman AD: GADD153/CHOP, a DNA damage-inducible protein, 
reduced CAAT/enhancer binding protein activities and increased 
apoptosis in 32D c13 myeloid cells.  Cancer Res 1996, 56:3250-3256.
15. Matsumoto M, Minami M, Takeda K, Sakao Y, Akira S: Ectopic expression 
of CHOP (GADD153) induces apoptosis in M1 myeloblastic leukemia 
cells.  FEBS Lett 1996, 395:143-147.
16. Qian J, Chen Z, Lin J, Wang W, Cen J: Decreased expression of CCAAT/
enhancer binding protein zeta (C/EBPzeta) in patients with different 
myeloid diseases.  Leuk Res 2005, 29:1435-1441.
17. Agrawal S, Hofmann WK, Tidow N, Ehrich M, Boom D van den, 
Koschmieder S, Berdel WE, Serve H, Müller-Tidow C: The C/EBPδ tumor 
suppressor is silenced by hypermethylation in acute myeloid leukemia.  
Blood 2007, 109:3895-3905.
18. Hackanson B, Bennett KL, Brena RM, Jiang J, Claus R, Chen SS, Blagitko-
Dorfs N, Maharry K, Whitman SP, Schmittgen TD, Lübbert M, Marcucci G, 
Bloomfield CD, Plass C: Epigenetic modification of CCAAT/enhancer 
binding protein A expression in acute myeloid leukemia.  Cancer Res 
2008, 68:3142-3151.
19. Jost E, do ON, Wilop S, Herman JG, Osieka R, Galm O: Aberrant DNA 
methylation of the transcription factor C/EBPα in acute myelogenous 
leukemia.  Leuk Res 2009, 33:443-449.
20. Herman JG, Graff JR, Myöhänen S, Nelkin BD, Baylin SB: Methylation-
specific PCR: a novel PCR assay for methylation status of CpG islands.  
Proc Natl Acad Sci USA 1996, 93:9821-9826.
doi: 10.1186/1756-9966-29-54
Cite this article as: Wang et al., Methylation status of DDIT3 gene in Chronic 
Myeloid Leukemia Journal of Experimental & Clinical Cancer Research 2010, 
29:54
Received: 7 April 2010 Accepted: 23 May 2010 
Published: 23 May 2010
This article is available from: http://www.jeccr.com/content/29/1/54 © 2010 Wang et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Experimental & Clinical Cancer Research 2010, 29:54